From the wire: Creganna-Tactx Medical and Boston Biomedical Associates (BBA) have announced a joint venture partnership under which Creganna-Tactx Medical customers will have dedicated access to clinical, regulatory and quality expertise and consulting services. The joint venture company will be co-located at BBA’s Massachusetts and California facilities and staffed by experienced regulatory and quality professionals who will have a dedicated focus on Creganna-Tactx Medical customers.
Creganna-Tactx Medical, headquartered in Galway, Ireland, provides outsourced solutions to medical device manufacturers. The company specialises in design and manufacturing of delivery devices for minimally and less invasive therapies. BBA is a clinical research and regulatory/quality affairs organisation that provides consulting services to companies developing and commercialising medical devices. The company also has extensive expertise in minimally and less invasive therapeutic products.
Under the partnership agreement and by leveraging BBA’s extensive experience, expertise and consulting services, Creganna-Tactx Medical will now provide a broad range of quality and regulatory support to its customers. These include development of appropriate regulatory and clinical strategies, regulatory submission development and liaison services, management of clinical trials and associated consulting services to achieve successful product approval and commercialization support. The service will be provided for a global market to include worldwide approval pathways and international regulatory support.